The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck.
Vassiliki Saloura
No relevant relationships to disclose
Ezra E.W. Cohen
No relevant relationships to disclose
Lisa F. Licitra
Consultant or Advisory Role - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; Pfizer
Salem Billan
No relevant relationships to disclose
Jose Dinis
Consultant or Advisory Role - Amgen; Merck Serono
Honoraria - Merck Serono
Steen Lisby
Employment or Leadership Position - Genmab
Stock Ownership - Genmab
Thomas Christoph Gauler
Consultant or Advisory Role - Genmab
Honoraria - Genmab
Research Funding - Genmab